---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-001001"
form_type: "8-K"
ticker: "WGRX"
cik: "0002030763"
company_name: "Wellgistics Health, Inc."
filed_at: "2026-01-08T23:59:59+00:00"
generated_at: "2026-05-16T11:15:57.034871+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Wellgistics Health issues $3.125M convertible notes at 20% OID; sets 2026 target of 500 pharmacy onboardings/month

## Summary
- Issued up to $3,125,000 aggregate principal convertible notes; purchase price $2.5M (20% original issue discount).
- Notes mature at earlier of 6 months or close of $2M+ qualified equity financing; conversion floor price $0.08.
- Placement agent Dawson James Securities received 6.5% commission ($162,500) and warrants for 5% of gross proceeds.
- 2026 outlook: integrate EinsteinRx AI into pharmacy POS; target onboarding up to 500 pharmacies/month into Wellgistics Pharmacy Network.
- Company expanding manufacturer relationships for diabetes, GLP-1, and cardiometabolic drugs; PharmacyChain resource assessment ongoing.

## SEC filing metadata
- accession: 0001493152-26-001001
- form_type: 8-K
- ticker: WGRX
- cik: 0002030763
- company_name: Wellgistics Health, Inc.
- filed_at: 2026-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2030763/000149315226001001/0001493152-26-001001-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2030763/000149315226001001/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-001001
- JSON: https://secwatch.observer/filing/0001493152-26-001001.json
- Plain text: https://secwatch.observer/filing/0001493152-26-001001.txt

## Source-grounded claims
- claim_id: 210e3fda725be8b0698906864dbe675327078e1a
  claim: Wellgistics Health, Inc. incurred convertible notes of up to $3,125,000 in aggregate principal amount with certain investors at 0% except in the event of an event of default, in which case, the default intere maturing on (a) the six (6) month anniversary of the date of issuance of the Notes, or (b) the date of closing of the next issuance and sale of capital stock of the Comp.
  evidence_excerpt: On January 5, 2026, Wellgistics Health, Inc. (the “Company”), entered into a note purchase agreement (the “Note Purchase Agreement”) with certain investors (the “Investors”) whereby the Company agreed to issue and sell to the Investors in a private offering up to $3,125,000 in aggregate principal amount (the “Aggregate Principal Amount”) of convertible promissory notes (the “Notes”) (the “Offering”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/2030763/000149315226001001/0001493152-26-001001-index.htm
- claim_id: 6a107b4bde593f717b478a80bf9c6f448fea8322
  claim: Wellgistics Health, Inc. entered into Placement Agency Agreement with Dawson James Securities, Inc. (the “Placement Agent”) (effective 2026-01-05).
  evidence_excerpt: On January 5, 2026, in connection with the Offering, the Company entered into a placement agency agreement, a copy of which is filed as Exhibit 10.3 to this Current Report on Form 8-K (the “Placement Agency Agreement”) with Dawson James Securities, Inc. (the “Placement Agent”), pursuant to which the Placement Agent agreed to act as the Company’s placement agent in connection with the Offering.
  evidence_url: https://www.sec.gov/Archives/edgar/data/2030763/000149315226001001/0001493152-26-001001-index.htm
- claim_id: e30fd75f0d8297a2bcab7774ed40e75e6c286020
  claim: Wellgistics Health, Inc. entered into Note Purchase Agreement with certain investors (the "Investors") valued at up to $3,125,000 in aggregate principal amount (effective 2026-01-05).
  evidence_excerpt: On January 5, 2026, Wellgistics Health, Inc. (the “Company”), entered into a note purchase agreement (the “Note Purchase Agreement”) with certain investors (the “Investors”) whereby the Company agreed to issue and sell to the Investors in a private offering up to $3,125,000 in aggregate principal amount (the “Aggregate Principal Amount”) of convertible promissory notes (the “Notes”) (the “Offering”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/2030763/000149315226001001/0001493152-26-001001-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.